{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:43:42Z","timestamp":1735584222595},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Recent successes in monitoring and diagnosing a variety of tumors using <jats:sup>99m<\/jats:sup>Tc-PEG4-E[PEG4-c(RGDfK)]2 (<jats:sup>99m<\/jats:sup>Tc-3PRGD2) single-photon emission computed tomography (SPECT) imaging encouraged us to expand the use of this tracer. This case-control study aimed to evaluate the feasibility of <jats:sup>99m<\/jats:sup>Tc-3PRGD2 imaging for detecting choroidal melanoma (CM) and for monitoring tumor response to plaque brachytherapy (PB). Ten consecutive patients with CM who underwent <jats:sup>99m<\/jats:sup>Tc-3PRGD2 imaging before and 3 months after PB were reviewed. The tumor-to-occipital bone (T\/O) and mirrored contralateral normal tissue-to-occipital bone (N\/O) ratios were calculated by region of interest analysis at baseline and 3 months post-PB. T\/O values were compared between patients with CM with comorbid secondary retinal detachment (RD) and those without RD. The relationship between T\/O value and tumor volume was also investigated. <jats:sup>99m<\/jats:sup>Tc-3PRGD2\u200aSPECT\/CT showed focal uptake in CM. The mean T\/O ratio before PB was 1.90\u200a\u00b1\u200a1.26 and the mean N\/O ratio was 0.80\u200a\u00b1\u200a0.21 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a.02). The <jats:sup>99m<\/jats:sup>Tc-3PRGD2 concentrations in 5 patients with CM with RD were higher (T\/O\u200a=\u200a2.69\u200a\u00b1\u200a1.39) than in those without secondary RD (T\/O\u200a=\u200a1.10\u200a\u00b1\u200a0.18) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a.008). T\/O ratios at 3 months post-PB were significantly lower than that at baseline (1.23\u200a\u00b1\u200a0.59, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a.03). There was a linear relationship between T\/O and tumor volume (<jats:italic toggle=\"yes\">y<\/jats:italic>-hat\u200a=\u200a0.028\u200a+\u200a0.003<jats:italic toggle=\"yes\">x<\/jats:italic>, <jats:italic toggle=\"yes\">R<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0.768, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001). The 95% confidence interval for the (T\/O)\/volume ratio was 0.002 to 0.005. <jats:sup>99m<\/jats:sup>Tc-3PRGD2 imaging is a feasible modality for the diagnosis of CM. Furthermore, follow-up for at least 20 months after PB indicated that coanalysis of <jats:sup>99m<\/jats:sup>Tc-3PRGD2 imaging and tumor volume may provide a promising prognostic predictor in patients with CM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000012441","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T22:40:00Z","timestamp":1538606400000},"page":"e12441","source":"Crossref","is-referenced-by-count":5,"title":["99mTc-3PRGD2 single-photon emission computed tomography\/computed tomography for the diagnosis of choroidal melanoma"],"prefix":"10.1097","volume":"97","author":[{"given":"Bing","family":"Yan","sequence":"first","affiliation":[{"name":"Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology"},{"name":"Department of Nuclear Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Fu","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany"},{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueming","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Wei","sequence":"additional","affiliation":[{"name":"Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojie","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute & Fu Wai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0974-620X.94718","article-title":"Choroidal melanoma","volume":"5","author":"Singh","year":"2012","journal-title":"Oman J Ophthalmol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/ICU.0000000000000041","article-title":"Choroidal melanoma: clinical features, classification, and top 10 pseudomelanomas","volume":"25","author":"Shields","year":"2014","journal-title":"Curr Opin Ophthalmol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS rep-ort No. 28","volume":"124","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2013.11.008","article-title":"The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma","volume":"13","year":"2014","journal-title":"Brachytherapy"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjophthalmol-2012-302490","article-title":"Local treatment failure after globe-conserving therapy for choroidal melanoma","volume":"97","author":"Chang","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s10967-015-3928-5","article-title":"99mTc-3P-RGD2 molecular imaging targeting integrin alphavbeta3 in head and neck squamous cancer xenograft","volume":"304","author":"Yan","year":"2015","journal-title":"J Radioanal Nucl Chem"},{"key":"R7-20230915","first-page":"36","article-title":"Angiogenesis capacity as a diagnostic marker for human eye tumors","volume":"86","author":"Tapper","year":"1979","journal-title":"Surgery"},{"key":"R8-20230915","first-page":"49","article-title":"Expression and significance of factors related to angiogenesis in choroidal melanoma","volume":"4","author":"Xu","year":"2011","journal-title":"Int J Ophthalmol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/978-1-61779-166-6_27","article-title":"Integrins in tumor angiogenesis and lymphangiogenesis","volume":"757","author":"Foubert","year":"2012","journal-title":"Methods Mol Biol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ceb.2016.07.008","article-title":"alphavbeta3 Integrin and tumour blood vessels-learning from the past to shape the future","volume":"42","author":"Demircioglu","year":"2016","journal-title":"Curr Opin Cell Biol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1021\/mp3002733","article-title":"RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis","volume":"9","author":"Danhier","year":"2012","journal-title":"Mol Pharm"},{"issue":"(suppl 1)","key":"R12-20230915","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1007\/s00259-011-2028-1","article-title":"Radiolabelled RGD peptides for imaging and therapy","volume":"39","author":"Gaertner","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2174\/1566524013666131111115347","article-title":"Development of RGD-based radiotracers for tumor imaging and therapy: translating from bench to bedside","volume":"13","author":"Liu","year":"2013","journal-title":"Curr Mol Med"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2310\/7290.2011.00006","article-title":"99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin alphaVbeta3 expression","volume":"10","author":"Zhou","year":"2011","journal-title":"Mol Imaging"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s00259-011-1901-2","article-title":"Differential diagnosis of solitary pulmonary nodules using (9)(9)mTc-3P(4)-RGD(2) scintigraphy","volume":"38","author":"Ma","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s11307-010-0385-y","article-title":"Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin alphavbeta3-selective radiotracer 99mTc-3PRGD 2 in non-human primates","volume":"13","author":"Jia","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2967\/jnumed.112.107821","article-title":"Integrin alphavbeta3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2","volume":"53","author":"Zhao","year":"2012","journal-title":"J Nucl Med"},{"key":"R18-20230915","first-page":"351","article-title":"(99m)Tc-3P-RGD2 micro-single-photon emission computed tomography\/computed tomography provides a rational basis for integrin alphavbeta3-targeted therapy","volume":"29","author":"Fu","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2174\/1389557515666150909144606","article-title":"Molecular Imaging of Breast Cancer: Role of RGD Peptides","volume":"15","author":"Chakravarty","year":"2015","journal-title":"Mini Rev Med Chem"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.111.098988","article-title":"99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study","volume":"53","author":"Zhu","year":"2012","journal-title":"J Nucl Med"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/jpet.112.202622","article-title":"Monitoring tumor response to linifanib therapy with SPECT\/CT using the integrin alphavbeta3-targeted radiotracer 99mTc-3P-RGD2","volume":"346","author":"Ji","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"R22-20230915","first-page":"39","article-title":"Monitoring glioma growth and tumor necrosis with the U-SPECT-II\/CT scanner by targeting integrin alphavbeta3","volume":"12","author":"Shao","year":"2013","journal-title":"Mol Imaging"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.nucmedbio.2016.02.006","article-title":"Comparison of biological properties of 99mTc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging","volume":"43","author":"Zhao","year":"2016","journal-title":"Nucl Med Biol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.01.007","article-title":"Iminodiacetic acid as bifunctional linker for dimerization of cyclic RGD peptides","volume":"48","author":"Xu","year":"2017","journal-title":"Nucl Med Biol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.eye.6700720","article-title":"Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas","volume":"18","author":"Richtig","year":"2004","journal-title":"Eye (Lond)"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5301\/ejo.5000049","article-title":"Initial PET\/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients","volume":"22","author":"Freton","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1097\/RLU.0000000000001275","article-title":"18F-FDG PET\/CT and melanoma: value of fourth and subsequent posttherapy follow-up scans for patient management","volume":"41","author":"Mena","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10147-013-0538-5","article-title":"Clinicopathological correlation for the role of fluorodeoxyglucose positron emission tomography computed tomography in detection of choroidal malignant melanoma","volume":"19","author":"Matsuo","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/1450-1147.167599","article-title":"Poor uptake of fluorodeoxyglucose in positron emission tomography-computed tomography scan for intraocular choroidal melanoma in Asian Indian eyes","volume":"15","author":"Sharma","year":"2016","journal-title":"World J Nucl Med"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2147\/OPTH.S28863","article-title":"Current and emerging treatment options for uveal melanoma","volume":"7","author":"Pereira","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","article-title":"Tumor angiogenesis: molecular pathways and therapeutic targets","volume":"17","author":"Weis","year":"2011","journal-title":"Nat Med"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2010.02.002","article-title":"Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles","volume":"149","author":"Vachutinsky","year":"2011","journal-title":"J Control Release"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2012.03.008","article-title":"Anti-angiogenesis therapy in cancer: current challenges and future perspectives","volume":"320","author":"Shojaei","year":"2012","journal-title":"Cancer Lett"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2174\/1381612822666151209153636","article-title":"RGD-based therapy: principles of selectivity","volume":"22","author":"Rubtsov","year":"2016","journal-title":"Curr Pharm Des"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201810050-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:00:01Z","timestamp":1694815201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201810050-00015"}},"subtitle":["A preliminary STROBE-compliant observational study"],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":34,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000012441","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}